Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. Issue 1 (12th August 2017)

• Record Type: Journal Article
• Authors: Vaca, Silvia Daniela; Connolly, Ian David; Ho, Clement; Neal, Joel; Hayden Gephart, Melanie
• Is Part Of: Neurosurgery. Volume 82:Issue 1(2018)
• Page Start: E6
• Page End: E14
• Publication Date: 2017-08-12
• Subjects: Brain metastasis -- Leptomeningeal disease -- Epidermal growth factor receptor -- Tyrosine kinase inhibitor -- Non-small cell lung cancer; Nervous system -- Surgery -- Periodicals; 617.48005
• DOI: 10.1093/neuros/nyx429
• Languages: English
• ISSNs: 0148-396X

Abstract

Abstract: Brain metastasis is a serious complication of non-small cell lung cancer (NSCLC) affecting up to 40% of NSCLC patients. A subset of NSCLC tumors has mutations in the epidermal growth factor receptor (EGFR) gene, and determination of tumor EGFR mutation status is essential in guiding treatment decisions, as it directly affects the treatment approach. Patients with EGFR-mutated NSCLC have a higher cumulative incidence of brain metastases, and are especially sensitive to EGFR tyrosine kinase inhibitors (TKIs). Patients with newly diagnosed EGFR-mutated lung cancer presenting to a neurosurgeon with a new diagnosis of brain metastases now have a variety of treatment options available, including whole brain radiation therapy, stereotactic radiosurgery, surgical resection, chemotherapy, and targeted therapeutics such as the EGFR TKIs. In this review, we discuss the impact of EGFR mutation status on brain and leptomeningeal metastasis treatment considerations. Additionally, we present clinical cases of patients treated with EGFR TKIs alone and in combination with other therapies to highlight treatment alternatives.